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BACKGROUND: Maternal pregestational diabetes is a well-known risk factor for congenital anomalies. This
study analyses the spectrum of congenital anomalies associated with maternal diabetes using data from a
large European database for the population-based surveillance of congenital anomalies. METHODS: Data
from 18 population-based EUROCAT registries of congenital anomalies in 1990-2005. All malformed cases
occurring to mothers with pregestational diabetes (diabetes cases) were compared to all malformed cases in
the same registry areas to mothers without diabetes (non-diabetes cases). RESULTS: There were 669 diabetes
cases and 92,976 non diabetes cases. Odds ratios in diabetes pregnancies relative to non-diabetes pregnancies
comparing each EUROCAT subgroup to all other non-chromosomal anomalies combined showed signifi-
cantly increased odds ratios for neural tube defects (anencephaly and encephalocele, but not spina bifida)
and several subgroups of congenital heart defects. Other subgroups with significantly increased odds ratios
were anotia, omphalocele and bilateral renal agenesis. Frequency of hip dislocation was significantly lower
among diabetes (odds ratio 0.15, 95% CI 0.05–0.39) than non-diabetes cases. Multiple congenital anomalies
were present in 13.6 % of diabetes cases and 6.1 % of non-diabetes cases. The odds ratio for caudal regres-
sion sequence was very high (26.40, 95% CI 8.98–77.64), but only 17% of all caudal regression cases resulted
from a pregnancy with pregestational diabetes. CONCLUSIONS: The increased risk of congenital anomalies
in pregnancies with pregestational diabetes is related to specific non-chromosomal congenital anomalies and
multiple congenital anomalies and not a general increased risk. Birth Defects Research (Part A) 94:134–140,
2012.  2012 Wiley Periodicals, Inc.
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INTRODUCTION
Maternal diabetes is a well-known risk factor for con-
genital anomaly (CA). It has also been known for many
years that good metabolic control in the preconceptional
period decreases the risk of CA (Moelsted-Pedersen et al.,
1964; Greene, 1999; Kitzmiller et al., 2010). Maternal hyper-
glycemia is teratogenic, imposing the same risk of CA to
pregnant women with type 1 or type 2 diabetes (Schwartz
and Teramo, 2000; Farrel et al., 2002). Furthermore, the
relationship between maternal hyperglycemia in early
pregnancy and the frequency of CA seems to be linear
without any threshold level (Greene, 1999; Schwartz and
Teramo, 2000). However, several theories have been raised
in the literature concerning the primary etiologic factor
without a clear consensus (Zabiki et al., 2010).
It is estimated in publications from Europe and the
United States that 0.3% of all pregnant women have pre-
gestational diabetes (Sheffield et al., 2002; Penney et al.,
2003; Savona-Ventura et al., 2003) with the majority of
the women having type 1 diabetes. There has been a sig-
nificant increase in type 1 diabetes in children and young
adults born after the mid 1980s (Gale, 2002; Svensson
et al., 2002). Therefore, it is expected that there will be an
increase in the number of pregnant women with type 1
diabetes in the future. There is also a global increase in
type 2 diabetes, thus the number of pregnant women
with type 2 diabetes is also expected to increase.
In recent studies of pregnancies with pregestational di-
abetes, the risk of CA has been estimated to be between
5.0 and 11.9% (Casson et al., 1997, Sheffield et al., 2002;
Penney et al., 2003; Evers et al., 2004, Jensen et al., 2004)
compared to 2 to 3% in the background population
(Boyd et al., 2011). The types of CAs in diabetes pregnan-
cies differ from those in nondiabetic pregnancies, with a
higher proportion of anomalies affecting the central nerv-
ous system including neural tube defects (NTDs), the
heart, and the kidneys (Kucera, 1971; Becerra et al., 1990;
Schwartz and Teramo, 2000, Sheffield et al., 2002; Macin-
tosh et al., 2006; Correa et al., 2008). The rare malforma-
tion caudal regression sequence has a strong association
with maternal diabetes (Becerra et al., 1990; Greene, 1999;
Schwartz and Teramo, 2000). Sirenomelia has been
described as being the more severe form of caudal
regression sequence, although there are different opin-
ions in the literature (Das et al., 2002; Duesterhoeft et al.,
2007; Bruce et al., 2009). A recent multicenter-study
found that maternal diabetes was present in 5% of preg-
nancies with sirenomelia (Orioli et al., 2011). However,
published data on the specific types of CA in diabetes
pregnancies are mainly from small studies with only a
small number of malformed cases.
The aim of this study is to investigate the spectrum of
CA associated with pregestational maternal diabetes
using data from a large European database for the popu-
lation-based surveillance of congenital anomalies.
MATERIALS AND METHODS
The EUROCAT registries are population based and sur-
vey geographically defined populations. The methods of
case ascertainment within the EUROCAT registries are
described elsewhere (www.eurocat-network.eu). The regis-
tries are all based on multiple sources of information such
as hospital records, birth and death certificates, and post
mortem examinations, and include information about live
births (LB), fetal deaths (FD) with gestational age (GA)
greater than 20 weeks, and terminations of pregnancy af-
ter prenatal diagnosis of a fetal anomaly (TOPFA). All
major structural malformations, monogenic syndromes
and chromosomal anomalies are included in the database.
Minor anomalies are excluded. Data quality indicators for
all registries have been published (Loane et al., 2011).
The study included all cases of mothers with pregesta-
tional diabetes and born in the 18 EUROCAT registry
areas during 1990 to 2005. The 18 registries are: Norway,
Funen County (Denmark), Mainz and Saxony-Anhalt
(Germany), Northern Netherlands, Hainaut-Namur and
Antwerp (Belgium), Wales, Northern Region (United
Kingdom), Cork and Kerry (Ireland),Vaud (Switzerland),
Strasbourg and Iles de Reunion (France), Tuscany and
Emilia-Romagna (Italy), Basque Country (Spain), South
Portugal, and Malta. Some registries did not cover the
whole time period. The total number of births covered
during the study period was 3,729,230.
The central EUROCAT database was searched for all
possible International Classification of Diseases (ICD) ver-
sion 9 and 10 codes and written text for diabetes in the
variables ‘‘maternal illness before pregnancy’’ and
‘‘maternal illness during pregnancy’’, codes and text for
‘‘infant of diabetic mother’’ and insulin use recorded in
the variable ‘‘drug use in pregnancy’’ to find cases for
which maternal diabetes had been recorded. The cases
were then reviewed by the local registries to exclude those
with gestational diabetes. Controls were all malformed
babies or fetuses in the same registries without pregesta-
tional or known gestational diabetes (nondiabetic cases).
Data on diabetes and nondiabetic cases included type of
birth (LB, FD, or TOPFA), time of diagnosis, GA, birth
weight, one week survival, maternal age, maternal disease
before pregnancy, maternal disease during pregnancy and
codes for drug use. Up to eight anomalies and a syndrome
code (if present) per baby or fetus are coded according to
ICD9 or ICD10 with British Pediatric Association (BPA)
extensions, and the cases are allocated to subgroups of
anomalies based on the ICD BPA codes. One baby or fetus
may be allocated to more than one subgroup; for example,
spina bifida was included in the following subgroups: all
anomalies, nervous system, NTD, and spina bifida.
We did a complete evaluation of all congenital anoma-
lies registered for all diabetes cases. These cases were
classified into only one of the following groups: chromo-
somal cases, monogenic syndromes, isolated NTD, iso-
lated congenital heart defects, isolated renal anomalies,
other isolated anomalies, and multiple anomalies, using
the EUROCAT computer algorithm for multiple anoma-
lies followed by manual review of all potential multiple
cases (Garne et al., 2011). For the purposes of comparison
of anomaly group distribution, a random sample of twice
as many nondiabetic cases (n 5 1338) were classified and
reviewed in the same way.
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The VATER/VACTERL association (Botto et al., 1997) was
identified according to the specific ICD/BPA code (759895
and Q8726) and for most registries also by written text. The
VATER/VACTERL diagnosis was given locally by clinicians
or registries, not centrally on the basis of the presence of three
or more of the component anomaly codes. For the two
anomalies caudal regression sequence and sirenomelia, the
nondiabetic cases were searched for in the dataset based only
on written text description, because coding may be nonspe-
cific and heterogeneous. Analysis of caudal regression and
sirenomelia was restricted to registries with text information
describing the congenital anomalies for all cases.
Statistics
Statistical analysis was conducted using SPSS Statistics
version 17.0 (SPSS, Chicago, IL) and STATA version 9.0
(StataCorp LP, College Station, TX). The odds of having
each specific congenital anomaly subgroup among diabe-
tes cases was compared with the odds of having that spe-
cific congenital anomaly subgroup among nondiabetic
cases, to give crude odds ratios (ORs).
A logistic regression model was used to calculate ORs
for 86 EUROCAT nonindependent nonchromosomal
anomaly subgroups adjusting for registry, maternal age,
and year of birth (entered as a linear term). Because of the
many subgroups and the problem of spuriously statisti-
cally significant results by multiple testing, only nonchro-
mosomal anomaly subgroups with significantly increased
risk at p < 0.01 level or with minimum five diabetes cases
in the subgroup cases are presented in the Results. A ran-
dom sample of nondiabetic cases were selected using the
built-in SPSS select if function, which randomly selected
1338 nondiabetic cases of the total 92,976 nondiabetic
cases.
RESULTS
The study identified 669 cases notified to the EUROCAT
Central database to mothers with pregestational diabetes.
The number of nondiabetic congenital anomaly cases in
the same registries and the same time period was 92,976.
The percentage of pregestational diabetes among all babies
or fetuses with a congenital anomaly was 0.72%.
Descriptive Parameters
There was no difference in type of birth for diabetes
cases and nondiabetic cases with 573 live births (86%) and
79,349 (85%), respectively. Eleven percent of diabetes cases
resulted in a TOPFA (76 cases) compared with 13% of
nondiabetic cases (11,936). Fetal deaths occurred in 20 dia-
betes cases (3%) and 1691 nondiabetic cases (2%). Sixteen
percent of diabetes live births were diagnosed prenatally,
compared with 15% of the nondiabetic liveborn cases.
Maternal age at delivery was higher for diabetes cases
compared with nondiabetic cases and the background
populations, with 27% of diabetic mothers being 35 years
or older at the time of birth compared with 19% of the
nondiabetic mothers and 17% in the background popula-
tions. Mean maternal age for diabetes cases was 30.7
years (6SD 5.8) and for nondiabetic cases was 29.5 years
(6SD 5.7; p < 0.001).
Liveborn infants with congenital anomalies from diabe-
tes pregnancies were heavier (p < 0.001) and born at a
lower GA (p < 0.001) than nondiabetic liveborn cases. For
live born diabetes cases, 8% were born before 32 weeks’
gestation, 35% at 32 to 36 weeks, 47% at 37 to 39 weeks,
and 7% at 40 weeks or greater. For all nondiabetic cases,
the respective percentages were 3, 12, 42, and 39%. Median
birth weight for GA was higher for the malformed diabetes
cases than for the malformed nondiabetic cases for all live-
born cases born with GA less than 42 weeks (Fig. 1).
Among the diabetes cases, there were 344 males
(51.4%), 317 females (47.4%), and three cases with
indeterminate sex (0.4%). Sex was unknown for four
TOPFA cases and one fetal death (0.7%). Among nondia-
betic cases, 54.7% were males, 43.2% were females, and
0.3% were indeterminate, and 1.8% cases were unknown.
The ratio of males to females for diabetes cases was 1.09
(95% confidence interval [CI], 0.92–1.25); compared with
the ratio of males to females for nondiabetic cases at 1.27
(95% CI, 1.25–1.28)
Figure 1. Median birth weight for gestational age groups for
liveborn diabetes cases and nondiabetic cases with congenital
anomalies. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
Table 1
Distribution of Type of Anomaly for Diabetic Cases
and a Random Sample of Nondiabetic Cases
Congenital anomaly
Diabetic
cases (%)
Nondiabetic
cases (%)
Chromosomal anomaly 38 (5.7) 153 (11.4)
Monogenic syndrome 14 (2.1) 34 (2.5)
Isolated neural tube defects 31 (4.6) 41 (3.1)
Isolated heart defects 256 (38.3) 333 (24.9)
Isolated renal anomaly 53 (7.9) 131 (9.8)
Other isolated anomaly 186 (27.8) 565 (42.2)
Multiple anomaly 91 (13.6) 81 (6.1)
Total 669 (100) 1338 (100)
All cases counted only once.
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Type of Anomaly
Among diabetes cases there were 38 chromosomal
(5.7%) and 631 nonchromosomal cases (94.3%). For all
nondiabetic cases, there were 11,673 chromosomal
(12.5%) and 81,303 (87.5%) nonchromosomal cases. The
overall OR for nonchromosomal versus chromosomal
cases was 2.38 (95% CI, 1.72–3.31; p < 0.001).
Cases were classified by type of anomaly using the
computer algorithm and manual review (Table 1). Iso-
lated congenital heart defects were present in 38.3% and
multiple anomalies in 13.6% of the diabetes cases com-
pared to 24.9% isolated congenital heart defects and 6.1%
multiple anomalies in the random sample of the nondia-
betic cases (n 5 1338)
Table 2 shows the ORs for each EUROCAT subgroup
compared with all other nonchromosomal anomalies com-
bined. A subgroup is shown if there are at least five diabe-
tes cases or if the difference is significant (p < 0.01). Adjust-
ing for maternal age, time period, and registry made no
difference in the overall findings.
Table 2
Congenital anomaly subgroups in diabetes and non-diabetes pregnancies, unadjusted and adjusted odds ratios
(OR)1, 18 EUROCAT registries 1990–2005
Congenital anomaly
Non-chromosomal
diabetes cases
Non-chromosomal
non-diabetes cases OR 95% CI OR (adjusted)
95% CI
Nervous system 72 7733 1.23 0.96-1.57
Neural Tube Defects* 41 3485 1.55 1.13–2.13 1.57 1.14–2.16
Anencephalus and similar* 19 1306 1.90 1.20–3.01 1.90 1.20–3.02
Encephalocele* 9 364 3.22 1.65–6.26 3.27 1.67–6.39
Spina Bifida 13 1815 0.92 0.53–1.60
Hydrocephaly 14 1744 1.04 0.61–1.76
Microcephaly 9 820 1.42 0.73–2.75
Eye 10 1935 0.66 0.35–1.24
Ear, face and neck 8 1463 0.70 0.35–1.41
Anotia* 3 85 4.56 1.44–14.47 4.37 1.36–14.03
Congenital heart defects* 323 26228 2.20 1.88–2.58 2.07 1.76–2.43
Common arterial truncus 5 229 2.83 1.16–6.88 2.59 1.06–6.35
Transposition of great vessels* 17 1128 1.97 1.21–3.20 2.00 1.23–3.26
Single ventricle 5 269 2.41 0.99–5.85 2.57 1.05–6.28
Ventricular septal defect* 134 12617 1.47 1.21–1.78 1.43 1.18–1.74
Atrial septal defect* 101 6305 2.27 1.83–2.81 2.15 1.72–2.68
Atrioventricular septal defect 11 661 2.16 1.19–3.95 2.21 1.21–4.04
Tetralogy of Fallot 12 1004 1.55 0.87–2.76
Pulmonary valve stenosis 15 1914 1.01 0.60–1.69
Hypoplastic left heart 5 867 0.74 0.31–1.79
Coarctation of aorta* 18 1230 1.91 1.19–3.06 1.84 1.11–3.03
Respiratory 11 1994 0.71 0.39–1.28
Oro-facial clefts* 24 5563 0.54 0.36–0.81 0.56 0.37–0.84
Cleft lip with or without palate 14 3397 0.52 0.31–0.88 0.55 0.32–0.94
Cleft palate 10 2166 0.59 0.31–1.10
Digestive system 45 7162 0.80 0.59–1.08
Oesophageal atresia 7 870 1.04 0.49–2.19
Ano-rectal atresia and stenosis 11 1082 1.32 0.72–2.39
Diaphragmatic hernia 8 910 1.13 0.56–2.29
Abdominal wall defects 15 1513 1.28 0.77–2.15
Omphalocele* 13 742 2.28 1.31–3.97 2.32 1.33– 4.04
Urinary 85 12175 0.88 0.70–1.11
Bilateral renal agenesis 10 626 2.08 1.11–3.90 2.43 1.29–4.57
Renal dysplasia 11 1159 1.23 0.67–2.23
Congenital hydronephrosis 26 4241 0.78 0.53–1.16
Genital 39 6298 0.78 0.57–1.09
Hypospadias 28 4857 0.73 0.50–1.07
Limb* 85 16449 0.61 0.49–0.77 0.61 0.48–0.78
Limb reduction 16 2045 1.01 0.61–1.66
Upper limb reduction 9 1443 0.80 0.41–1.55
Lower limb reduction 7 761 1.19 0.56–2.51
Club foot–talipes equinovarus 22 3896 0.72 0.47–1.10
Hip dislocation/dysplasia* 4 3405 0.15 0.05–0.39 0.15 0.06–0.41
Polydactyly 19 2924 0.83 0.53–1.32
Syndactyly* 4 2174 0.23 0.09–0.62 0.19 0.06–0 .59
Musculo-skeletal* 46 4057 1.50 1.11–2.02 1.66 1.22–2.24
Other malformations 17 3448 0.63 0.39–1.01
Disorders of skin* 3 1769 0.21 0.07–0.67 0.19 0.05–0.78
Genetic syndromes 1 microdeletions 17 2251 0.97 0.60–1.58
*adjusted for maternal age, year and registry, *p value < 0.01
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Significantly increased ORs were found for: neural tube
defects (anencephaly and encephalocele, but not spina
bifida). For a number of congenital heart defects, the risk
was increased. However, the ORs for tetralogy of Fallot
and single ventricle were raised, but this did not reach sta-
tistical significance, whereas the ORs for pulmonary valve
stenosis and hypoplastic left heart were not raised at all.
Other subgroups with significantly raised ORs were ano-
tia, omphalocele, and bilateral renal agenesis.
Subgroups less likely to be associated with diabetes
included limb defects in general, and hip dislocation
(OR, 0.15; 95% CI, 0.05–0.39) and syndactyly in particular
(OR, 0.23; 95% CI, 0.09–0.62). Both cleft lip (with or with-
out cleft palate) and isolated cleft palate are less likely to
be associated with diabetes, but this was only statistically
significant for cleft lip with or without palate (OR, 0.52;
95% CI, 0.31–0.88).
There were three cases of VATER/VACTERL associ-
ated with maternal diabetes (OR, 3.37; 95% CI, 1.07–
10.65; Table 3). The component anomaly anal atresia was
slightly but not significantly increased (OR, 1.32; 95% CI,
0.72–2.40), but the component anomalies esophageal atre-
sia (OR, 1.04; 95% CI, 0.49–2.19) and limb reduction
defect (OR, 1.01; 95% CI, 0.61–1.66) showed no evidence
of association with diabetes.
Among registries with text descriptions of all malforma-
tions, we found four diabetes cases with caudal regression
sequence and one diabetes case with sirenomelia. There
were 21 nondiabetic cases diagnosed with caudal regres-
sion sequence and 15 nondiabetic cases with sirenomelia.
The difference in frequency of caudal regression sequence
between diabetes cases and nondiabetic cases was highly
significant (OR, 26.40; 95% CI, 8.98–77.64; p < 0.0001).
However, only 17% of all babies or fetuses with caudal
regression sequence and 6.3% of those with sirenomelia
were from a pregnancy with pregestational diabetes.
DISCUSSION
This study has to our knowledge presented the largest
case series of malformed babies or fetuses of mothers
with pregestational diabetes. We cannot directly assess
the overall relative risk of CA associated with maternal
diabetes, because we do not have a comparison group of
nonmalformed babies. However, our data suggest that
the overall risk of CA associated with diabetes is more
than doubled; 0.7% of babies with CA were associated
with maternal diabetes, which is more than twofold the
population prevalence of maternal diabetes of 0.3% usu-
ally estimated (Sheffield et al., 2002; Penney et al., 2003;
Savona-Ventura et al., 2003). This finding is consistent also
with the OR of 2.38 for nonchromosomal anomalies com-
pared with chromosomal anomalies, assuming that diabe-
tes is not associated with chromosomal anomalies and
accounting for the slightly higher maternal age in diabetes
cases. There is good evidence that glycemic control
reduces the risk of congenital anomaly (Jensen et al., 2004;
Kitzmiller et al., 2010). Our data represent the average sit-
uation across 18 registry areas in Europe during 1990 to
2005. As a result of glycemic control possibly improving in
populations, the overall level of risk of congenital anoma-
lies associated with diabetes should decrease.
The risk found in our study is consistent with other
studies that compare anomaly rate in cohorts of diabetes
pregnancies to the background population (Casson et al.,
1997; Penney et al., 2003; Evers et al., 2004; Jensen et al.,
2004). In some of these studies, the documentation of CA
in the background population was not entirely compara-
ble to the diabetes population, leaving the possibility that
risks were inflated by relatively more assiduous docu-
mentation of CA in diabetic pregnancy outcomes. Only
one study from Hungary, where more than half the pop-
ulation took periconceptional folic acid, found a lower
increase in risk (OR, 1.5; 95% CI 1.1 – 2.0) for major CA
in type 1 diabetes pregnancies compared with nondia-
betic pregnancies (Banhidy et al., 2010).
Our study did not find statistically significant differen-
ces in the likelihood of prenatal diagnosis or vital status
at birth between diabetic and nondiabetic cases. The mal-
formed live-born infants from pregestational diabetes
pregnancies had higher birth weight and lower GA com-
pared with the nondiabetic malformed cases. The lower
GA is well explained by the induction of birth at GA 38
weeks for many pregnancies with pregestational diabetes
because of the risk of macrosomia. Our data do not sup-
port a male predominance in infants with CA from dia-
betes pregnancies as published from the Netherlands
(Evers et al., 2009).
Our finding that diabetes is associated with anencepha-
lus and encephalocele, but not spina bifida, requires fur-
ther investigation. Most other diabetes studies have too
few cases to classify NTDs into subgroups. Correa et al.
(2008) found a significant risk for anencephalus, but not
spina bifida or encephalocele, but this was based on only
three to four diabetes-exposed cases of each of these
anomalies. It is well known that folic acid taken during
the periconceptional period reduces the risk of NTDs.
Women with pregestational diabetes are advised to plan
their pregnancies and to optimize their diabetic control
before pregnancy. At this stage, women with diabetes
Table 3
VATER/VACTERL Association, Caudal Regression Sequence, and Sirenomelia in Diabetic Nondiabetic
Pregnancies in Registries with Text Description of the Congenital Anomalies: 17 EUROCAT registries, 1990–2005a
Subgroups
Diabetic
cases
Nondiabetic
cases OR 95% CI
OR
(adjusted)b 95% CI
VATER/VACTERL association 3 117 3.37 1.07 - 10.65 3.47 1.09-11.04
Caudal regression sequence 4 20 26.40 8.98 - 77.64 22.06 6.68–68.72
Sirenomelia 1 15 8.73 1.15 - 66.24 6.54 0.84–51.13
aSeventeen registries with text information for congenital anomaly diagnoses: total nonchromosomal diabetes cases, n 5354; total non-
chromosomal nondiabetic cases, n 5 46,223.
bAdjusted for maternal age, year and registry.
OR, odds ratio; CI, confidence interval.
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should also be encouraged to take folic acid. The advised
dose is 5 mg, as recommended for women with a previ-
ous NTD pregnancy (Wilson, 2003; Kitzmiller et al.,
2010), although there is not full agreement (Kitzmiller
et al., 2010). Evidence suggests that folic acid is more
protective against spina bifida than anencephaly and en-
cephalocele (de Wals et al., 2007), and further research is
needed on the complex relationships among diabetes, fo-
lic acid, and type of NTD.
Our study showed that congenital heart defects were
2.2-fold more frequent in diabetes pregnancies relative to
other CAs, and congenital heart defects accounted for the
vast majority of excess risk of CA among diabetes exposed
pregnancies. ORs were higher for atrial septal defect
(ASD; 2.27; 95% CI, 1.83–2.81) than (ventricular septal
defect (VSD); OR, 1.47; 95% CI, 1.21–1.78). Congenital
heart defects requiring surgery with ORs as high as those
for ASD were common arterial truncus, common atrioven-
tricular canal, and single ventricle, although the last of
these did not reach statistical significance. There was no
evidence of an association with diabetes for pulmonary
valve stenosis and hypoplastic left hearts compared with
other CAs. The increased risk of ASD, VSD, and transposi-
tion of great arteries has been described by Correa et al.
(2008). ASD and ventricular septal defect (VSD) may in
part be increased because diabetes cases are more likely to
have a neonatal admission and thus more likely to have
an echocardiography performed.
The increased risk of anotia or microtia (Correa et al.,
2008) and bilateral renal agenesis (Sharpe et al., 2005;
Correa et al., 2008; Banhidy et al., 2010) has been found
by others previously. We have found only one published
study with specified data on omphalocele (Correa et al.,
2008), and the risk was significant for omphalocele only
as part of multiple defects (three exposed cases), not as
isolated omphalocele (one exposed case). Our study
included 13 diabetes cases with nonchromosomal ompha-
locele, resulting in an OR of 2.28 (95% CI, 1.31–3.97) com-
pared with nondiabetic cases. We could not confirm the
previously reported increased risks of hydrocephalus
(Correa et al., 2008), cleft lip (Correa et al., 2008), anal
atresia (Frias et al., 2007; Correa et al., 2008), limb reduc-
tion defects (Sharpe et al., 2005; Correa et al., 2008), and
hypospadia (Sharpe et al., 2005).
Based on case reports, VATER/VACTERL association
has been suggested to be related to maternal diabetes
(Castori et al., 2008). We also found a significantly
increased OR for VATER/VACTERL association, though
based on only three cases, but for the individual CA
involved in VATER/VACTERL association (esophageal
atresia, anal atresia, and limb reduction defects) we could
not find a significantly increased risk. We found that
13.6% of diabetes cases had multiple CAs compared with
6.1% among nondiabetic pregnancies
Our data suggest that diabetes is protective against hip
dislocation. We found that infants from diabetes preg-
nancies have a lower GA and a higher birth weight for
GA than nondiabetic cases. It is possible that it is the
lower GA of the diabetes births that is protective against
hip dislocation. A previous study from Australia found
that both high birth weight and high GA are independ-
ent risk factors for hip dislocation (Chan et al., 1997).
However, some caution should be exercised in the inter-
pretation of our results, because the diagnostic criteria
for hip dislocation vary and there was not a consistent
definition across Europe.
The rare malformation caudal regression sequence has
been described in the literature to have a strong associa-
tion with maternal diabetes (Greene, 1999; Schwartz and
Teramo, 2000; Becerra et al., 1990). In our study, we
found a highly significant increased risk of caudal regres-
sion in the diabetes pregnancies. However, only 17%
were from pregnancies with pregestational diabetes,
although there may have been some diabetes cases mis-
classified as nondiabetic cases. Our data suggest that,
whereas diabetes is a strong risk factor for caudal regres-
sion, etiologies other than diabetes are important, such as
mutations in the VANGL1 gene (Kibar et al., 2007).
The strength of our study is the high number of diabe-
tes cases and the standardized and specific classification
of all cases throughout the 18 registry areas. Our propor-
tion of diabetes exposure among congenital anomaly
cases of 0.7% was within the expected range. This would
not, however, bias ORs for specific CAs compared with
all other CAs. An additional limitation of our study is
that we lacked data on nonmalformed controls in our
dataset, which meant that we could not estimate the risk
of CA as a whole, or of subgroups relative to the nondia-
betic population, but could only analyze the specificity of
the association of certain malformations with diabetes. In
such a proportional analysis, when some anomalies are
significantly increased, others must be decreased; there-
fore, slightly decreased ORs do not necessarily reflect a
protective effect of diabetes. Because we tested many
subgroups, some statistically significant findings will also
arise by chance and may be considered ‘‘signals’’ for fur-
ther research when there is no supporting literature. It is
also a limitation that we do not have information on pre-
conceptional use of folic acid in our study population.
For some of our cases, we did not know whether the
woman had type 1 or type 2 diabetes. In this European
population with births during 1990 to 2005, it is likely
that most of the pregnancies had type 1 diabetes (Macin-
tosh et al., 2006; Whitworth et al., 2011). For the nondia-
betic control group, we deleted all cases with known ges-
tational diabetes. We recommend that future studies on
diabetes and congenital anomalies consider the distinc-
tion between type 1 and type 2 diabetes, and also con-
sider whether glycemic control reduces the risk of all or
selected diabetes-associated anomalies.
This study confirmed that the risk of major nonchro-
mosomal CA is at least twice as high in pregnancies with
pregestational diabetes compared with nondiabetic preg-
nancies. The risk is not a general increased risk, but it is
related to specific nonchromosomal anomalies and multi-
ple congenital anomalies. Although caudal regression
sequence is strongly related to pregestational diabetes,
other factors are important in the etiology of caudal
regression.
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